Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2009

View Archived Issues

GeoVax requests pre-IND meeting with FDA for therapeutic AIDS vaccine

Chugai is granted additional approvals in China for Xeloda and Avastin

EMEA accepts for review Pharming's MAA for Rhucin for hereditary angioedema

2009 influenza A (H1N1) vaccine generates immune response in children

Alimera Sciences starts pilot study of Iluvien in patients with macular edema

Alizyme provides update on sale of Cetilistat

BioSante and Cell Genesys confirm final exchange ratio for merger

Nifurtimox/eflornithine combination therapy for sleeping sickness now available

Pluristem Therapeutics doses first patient in phase I trial for PAD

Protalix Biotherapeutics presents preclinical data on pr-anti-TNF for arthritis

Sangamo BioSciences plans to initiate second CCR5-ZFP trial in HIV/AIDS

TGen commences clinical trials for OSI-906 for adrenocortical carcinoma

Icagen initiates proof-of-concept study of ICA-105665 in photosensitive epilepsy

E.C. grants Gilead Sciences conditional marketing approval for Cayston

ASP-2151 inhibits VZV and HSV-1/-2 activity in vitro and reduces HSV-1 pathology in vivo

Shionogi and GSK report data from phase II trials of HIV integrase inhibitor S/GSK-1349572

ZT-031 shows favorable PK as intranasal formulation in preclinical evaluation

4SC-201 shows favorable oral profile and tolerability in patients with solid tumors

BIIB-022 shown to be safe in phase I trial in relapsed/refractory solid tumor patients

NicOx discovers NO donors for the treatment of hypertension and other conditions

HDAC inhibitors for the treatment of cancer presented by Roche

Boehringer Ingelheim claims BK1 receptor antagonists as analgesics

Cycloindole derivatives for the treatment of HCV infection described by iTherX

Cephalon discloses histamine H3 antagonists for the treatment of sleep disorders

NicOx submits NDA to FDA for naproxcinod in osteoarthritis

FDA grants accelerated approval to Allos Therapeutics' Folotyn for relapsed or refractory PTCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...